|
Colorectal Carcinoma
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high anti-tumor activity against colorectal cancer.
|
31689241 |
2019 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
The only definitive ligand of NCR1 is influenza haemagglutinin, though there are believed to be others.
|
22212381 |
2012 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
There was enhanced spread of certain tumors in 129/Sv but not C57BL/6 Ncr1(gfp/gfp) mice, and influenza virus infection was lethal in both 129/Sv and C57BL/6 Ncr1(gfp/gfp) mice.
|
16565719 |
2006 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
Recently, we have identified a novel functional interaction between the lysis receptors NKp46 and NKp44 and the hemagglutinin of influenza and hemagglutinin-neuroaminidase of Sendai viruses.
|
14504081 |
2004 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
The influenza virus hemagglutinin (HA) was the first ligand identified for Ncr1/NKp46 followed by other viral, bacterial and even fungal ligands.
|
29026144 |
2017 |
|
Influenza
|
0.050 |
Biomarker
|
disease |
BEFREE |
In contrast, loss of NCR1 increased susceptibility to influenza virus, a result that is consistent with the role of NCR1 in the recognition of influenza Ag, hemagglutinin.
|
29440507 |
2018 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
Similarly, ligation of NKp46 on isolated NK cells resulted in a significant reduction in the HCV copy number detected in Huh-7.5/JFH-1 coculture (multiplicity of infection: 0.01) at an effector:target ratio of 5:1 (P < 0.005).
|
22505144 |
2012 |
|
Hepatitis C
|
0.030 |
Biomarker
|
disease |
BEFREE |
However, reports on NKp46 in hepatitis C are controversial.
|
22532190 |
2012 |
|
Hepatitis C
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The variation of the NKp46 proportion in individuals could be attributed to the diversity of HCV resistance observed in these individuals, which possibly reflects the clinical outcome of infection in patients.
|
26714120 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, we validate the prognostic value of NKp46 expression at diagnosis in AML.
|
29209559 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our longitudinal study of AML patients showed that the NCR(dull) phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR).
|
16940427 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, flow cytometry analysis of 20 samples of patients with acute myeloid leukemia (AML) (FAB M0-M5) revealed the expression of NKG2D (40%) and other natural cytotoxicity receptors (40% for NKp30, 74% for NKp44, 39% for NKp46) by a pool >15% of leukemic cells.
|
16239914 |
2005 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Most importantly, we showed that a toxin-conjugated 02 inhibits the growth of NKp46-positive cells; thus, exemplifying the potential of 02 in becoming an immunotherapeutic drug to treat NKp46-dependent diseases, such as, type I diabetes and NK and T cell related malignancies.
|
30536875 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that NKp46 is essential for the development of type 1 diabetes and highlight potential new therapeutic modalities for this disease.
|
20023661 |
2010 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our longitudinal study of AML patients showed that the NCR(dull) phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR).
|
16940427 |
2007 |
|
leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia.
|
21364281 |
2011 |
|
Multiple Sclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Rather, the major part of NCR1 expression was localised to astrocytes, and was considerably more pronounced in MS patients than controls.
|
22212381 |
2012 |
|
Multiple Sclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Moreover, patients with a first diagnosis of MS display the highest level of NCR1 when compared with patients pharmacologically treated with interferon-beta or natalizumab.
|
25115502 |
2014 |
|
Tuberculosis
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
NK cell lytic activity against M. tuberculosis-infected monocytes and NKp46 mRNA expression were reduced in tuberculosis patients with ineffective immunity to M. tuberculosis compared with findings in healthy donors.
|
11907104 |
2002 |
|
Tuberculosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
NK cell lytic activity against M. tuberculosis-infected monocytes and NKp46 mRNA expression were reduced in tuberculosis patients with ineffective immunity to M. tuberculosis compared with findings in healthy donors.
|
11907104 |
2002 |
|
Tuberculosis
|
0.020 |
Biomarker
|
disease |
LHGDN |
These results indicate that vimentin is involved in binding of NKp46 to M. tuberculosis H37Ra-infected mononuclear phagocytes.
|
17056548 |
2006 |
|
Complete atrioventricular block
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expressions of NKp46 and NKG2A were higher in CHB-H than in HS/CHB-L/CHB-NA.
|
28328926 |
2017 |
|
Complete atrioventricular block
|
0.020 |
Biomarker
|
disease |
BEFREE |
It was found that NKp46(+) NK cells were enriched in the livers of AHB and CHB patients.
|
23133672 |
2012 |
|
Childhood Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our longitudinal study of AML patients showed that the NCR(dull) phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR).
|
16940427 |
2007 |